Catalyst Biosciences


Industry Partner

Catalyst is a clinical-stage biopharmaceutical company focused on developing novel treatments for hemophilia and other rare bleeding disorders using our potent, subcutaneous (SQ) coagulation factors that promote prophylaxis therapy. We have completed enrolment and dosing in the Phase 2 trial of marzeptacog alfa (activated) – MarzAA, our SQ-dosed, next-generation Factor VIIa for the treatment of hemophilia A and B inhibitor patients. We have also initiated enrollment in a Phase 2b trial of dalcinonacog alfa – DalcA, a next-generation (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B.